BUZZ — Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
* Shares of Vir Biotechnology rise 11.7% to $11.85 premarket * Co inks collaboration and license agreement with Gilead for three candidates targeting selected solid tumor-associated antigens * VIR will be eligible to receive up to $135 million in total upfront and near-term preclinical milestone payments, and has the p